Alison E. Freimund
Impact in
- Reproductive Medicine top 10%
- Ovarian cancer diagnosis and treatment
- Oncology top 10%
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
- Drug Transport and Resistance Mechanisms
Papers in
- Oncology 5
- PARP inhibition in cancer therapy 4
- Cancer survivorship and care 1
-
- Ovarian cancer diagnosis and treatment 2
- Co-authors
- David D.L. Bowtell (1 shared paper)Jessica A. Beach (1 shared paper)Elizabeth L. Christie (1 shared paper)Linda Mileshkin (4 shared papers)Tarek M. Meniawy (2 shared papers)Michael Millward (2 shared papers)Virginia E. Paton (2 shared papers)Paul R. Harnett (1 shared paper)
- Journals
- Annals of Oncology (3 papers)JCO Precision Oncology (2 papers)The Lancet Oncology (1 paper)Hematology/Oncology Clinics of North America (1 paper)Integrative Cancer Therapies (1 paper)
- Partner nations
- AustraliaJapanUnited States
In The Last Decade
Alison E. Freimund
8 papers receiving 367 citations
Peers
Comparison fields: 5 of 35
- Reproductive Medicine 99
- Oncology 204
- Pediatrics, Perinatology and Child Health 21
- Cancer Research 17
- Obstetrics and Gynecology 9
Countries citing papers authored by Alison E. Freimund
This map shows the geographic impact of Alison E. Freimund's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison E. Freimund with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison E. Freimund more than expected).
Fields of papers citing papers by Alison E. Freimund
This network shows the impact of papers produced by Alison E. Freimund. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison E. Freimund. The network helps show where Alison E. Freimund may publish in the future.
Co-authors
The 25 scholars most cited alongside Alison E. Freimund, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2022 | 110 | |
| 2 | 2019 | 102 | |
| 3 | 2018 | 95 | |
| 4 | 2021 | 27 | |
| 5 | 2020 | 19 | |
| 6 | 2017 | 10 | |
| 7 | 2022 | 9 | |
| 8 | 2019 | 1 |
About Alison E. Freimund
Alison E. Freimund is a scholar working on Oncology, Reproductive Medicine, Obstetrics and Gynecology, Pediatrics, Perinatology and Child Health and Genetics, having authored 8 papers that have together received 373 indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (4 papers), Ovarian cancer diagnosis and treatment (2 papers), Cancer survivorship and care (1 paper), Endometrial and Cervical Cancer Treatments (1 paper), BRCA gene mutations in cancer (1 paper) and Prenatal Screening and Diagnostics (1 paper). The work is most often cited by research in Reproductive Medicine (99 citations), Oncology (204 citations), Pediatrics, Perinatology and Child Health (21 citations), Cancer Research (17 citations) and Obstetrics and Gynecology (9 citations). Alison E. Freimund has collaborated with scholars based in Australia, Japan and United States. Frequent co-authors include David D.L. Bowtell, Jessica A. Beach, Elizabeth L. Christie, Linda Mileshkin, Tarek M. Meniawy, Michael Millward, Virginia E. Paton, Paul R. Harnett, Joanne Lundy and Song Mu. Their work appears in journals such as Annals of Oncology, JCO Precision Oncology, The Lancet Oncology, Hematology/Oncology Clinics of North America and Integrative Cancer Therapies.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.